A
24.57
2.23 (9.98%)
| 前收盘价格 | 22.34 |
| 收盘价格 | 23.26 |
| 成交量 | 7,663,145 |
| 平均成交量 (3个月) | 924,053 |
| 市值 | 1,432,770,304 |
| 价格/销量 (P/S) | 34.32 |
| 股市价格/股市净资产 (P/B) | 1.20 |
| 52周波幅 | |
| 利润日期 | 30 Oct 2025 |
| 营业毛利率 | 1,798.26% |
| 营业利益率 (TTM) | -1,221.97% |
| 稀释每股收益 (EPS TTM) | 11.54 |
| 季度收入增长率 (YOY) | 6.60% |
| 总债务/股东权益 (D/E MRQ) | 3.61% |
| 流动比率 (MRQ) | 18.50 |
| 营业现金流 (OCF TTM) | -401.46 M |
| 杠杆自由现金流 (LFCF TTM) | -237.66 M |
| 资产报酬率 (ROA TTM) | -22.88% |
| 股东权益报酬率 (ROE TTM) | 60.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Agios Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.1
| 分析师共识 | -0.5 |
| 内部交易活动 | -2.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.10 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.65% |
| 机构持股比例 | 101.39% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 48.00 (HC Wainwright & Co., 95.36%) | 购买 |
| 中 | 32.00 (30.24%) | |
| 低 | 20.00 (JP Morgan, -18.60%) | 保留 |
| 平均值 | 32.13 (30.77%) | |
| 总计 | 5 购买, 3 保留 | |
| 平均价格@调整类型 | 25.25 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 26 Nov 2025 | 38.00 (54.66%) | 购买 | 27.38 |
| Truist Securities | 24 Nov 2025 | 32.00 (30.24%) | 购买 | 26.49 |
| JP Morgan | 21 Nov 2025 | 20.00 (-18.60%) | 保留 | 25.24 |
| B of A Securities | 20 Nov 2025 | 32.00 (30.24%) | 购买 | 24.57 |
| Goldman Sachs | 20 Nov 2025 | 25.00 (1.75%) | 保留 | 24.57 |
| HC Wainwright & Co. | 20 Nov 2025 | 48.00 (95.36%) | 购买 | 24.57 |
| 04 Sep 2025 | 56.00 (127.92%) | 购买 | 36.13 | |
| Leerink Partners | 20 Nov 2025 | 34.00 (38.38%) | 购买 | 24.57 |
| RBC Capital | 20 Nov 2025 | 28.00 (13.96%) | 保留 | 24.57 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合